Aguirre A., Dupree J.L., Mangin J.M., Gallo V. A functional role for EGFR signaling in myelination and remyelination. Nat. Neurosci. 2007, 10:990-1002.
Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori M., Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002, 8:35-40.
Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., Richards L. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 2001, 11:1911-1914.
Bianco R., Gelardi T., Damiano V., Ciardiello F., Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol. 2007, 39:1416-1431.
Bilder G.E., Krawiec J.A., McVety K., Gazit A., Gilon C., Lyall R., Zilberstein A., Levitzki A., Perrone M.H., Schreiber A.B. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 1991, 260:C721-C730.
Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
Bulic B., Ness J., Hahn S., Rennhack A., Jumpertz T., Weggen S. chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9:598-622.
Caja L., Sancho P., Bertran E., Ortiz C., Campbell J.S., Fausto N., Fabregat I. The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms. Biochem. Pharmacol. 2011, 82:1583-1592.
Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp. Cell Res. 2011, 317:1476-1489.
Chang C., Sternberg P.W. C. elegans vulval development as a model system to study the cancer biology of EGFR signaling. Cancer Metastasis Rev. 1999, 18:203-213.
Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., Ross J., Chien K.R., Lee K.F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 2002, 8:459-465.
Dalcq J., Pasque V., Ghaye A., Larbuisson A., Motte P., Martial J.A., Muller M. Runx3, Egr1 and Sox9b form a regulatory cascade required to modulate BMP-signaling during cranial cartilage development in zebrafish. PLoS One 2012, 7:e50140.
Dienstmann R., Brana I., Rodon J., Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011, 16:1729-1740.
Eccles S.A. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int. J. Dev. Biol. 2011, 55:685-696.
Fisher M.C., Clinton G.M., Maihle N.J., Dealy C.N. Requirement for ErbB2/ErbB signaling in developing cartilage and bone. Dev. Growth Differ. 2007, 49:503-513.
Friedrichs F., Zugck C., Rauch G.J., Ivandic B., Weichenhan D., Muller-Bardorff M., Meder B., El Mokhtari N.E., Regitz-Zagrosek V., Hetzer R., Schafer A., Schreiber S., Chen J., Neuhaus I., Ji R., Siemers N.O., Frey N., Rottbauer W., Katus H.A., Stoll M. HBEGF, SRA1, and IK: three cosegregating genes as determinants of cardiomyopathy. Genome Res. 2009, 19:395-403.
Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287:1969-1973.
Goishi K., Lee P., Davidson A.J., Nishi E., Zon L.I., Klagsbrun M. Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects. Mech. Dev. 2003, 120:811-822.
Harari P.M., Allen G.W., Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 2007, 25:4057-4065.
Hardy K.M., Booth B.W., Hendrix M.J., Salomon D.S., Strizzi L. ErbB/EGF signaling and EMT in mammary development and breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15:191-199.
Hauptmann G., Gerster T. Multicolor whole-mount in situ hybridization. Methods Mol. Biol. 2000, 137:139-148.
Holbro T., Hynes N.E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 2004, 44:195-217.
Iwamoto R., Mekada E. ErbB and HB-EGF signaling in heart development and function. Cell Struct. Funct. 2006, 31:1-14.
Jost M., Kari C., Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 2000, 10:505-510.
Kang N., Zhang J.H., Qiu F., Tashiro S., Onodera S., Ikejima T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett. 2010, 294:147-158.
Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., Schilling T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995, 203:253-310.
Laisney J.A., Braasch I., Walter R.B., Meierjohann S., Schartl M. Lineage-specific co-evolution of the Egf receptor/ligand signaling system. BMC Evol. Biol. 2010, 10:27.
Langer C.J. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:751-753.
Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267:1782-1788.
Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target. Oncol. 2009, 4:107-119.
Lu X., Kang Y. Epidermal growth factor signalling and bone metastasis. Br. J. Cancer 2010, 102:457-461.
Luetteke N.C., Phillips H.K., Qiu T.H., Copeland N.G., Earp H.S., Jenkins N.A., Lee D.C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 1994, 8:399-413.
Lyons D.A., Pogoda H.M., Voas M.G., Woods I.G., Diamond B., Nix R., Arana N., Jacobs J., Talbot W.S. erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafish. Curr. Biol. 2005, 15:513-524.
Ma A.C., Ward A.C., Liang R., Leung A.Y. The role of jak2a in zebrafish hematopoiesis. Blood 2007, 110:1824-1830.
Maccari R., Paoli P., Ottana R., Jacomelli M., Ciurleo R., Manao G., Steindl T., Langer T., Vigorita M.G., Camici G. 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorg. Med. Chem. 2007, 15:5137-5149.
Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., Roifman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
Miettinen P.J., Chin J.R., Shum L., Slavkin H.C., Shuler C.F., Derynck R., Werb Z. Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat. Genet. 1999, 22:69-73.
Morizot D.C., McEntire B.B., Della Coletta L., Kazianis S., Schartl M., Nairn R.S. Mapping of tyrosine kinase gene family members in a Xiphophorus melanoma model. Mol. Carcinog. 1998, 22:150-157.
Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
Osherov N., Gazit A., Gilon C., Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J. Biol. Chem. 1993, 268:11134-11142.
Pan S.N., Ma H.M., Su Z., Zhang C.X., Zhu S.Y., Du M.L. Epidermal growth factor receptor signalling mediates growth hormone-induced growth of chondrocytes from sex hormone-inhibited adolescent rats. Clin. Exp. Pharmacol. Physiol. 2011, 38:534-542.
Pang Y., Ge W. Epidermal growth factor and TGFalpha promote zebrafish oocyte maturation in vitro: potential role of the ovarian activin regulatory system. Endocrinology 2002, 143:47-54.
Pastore S., Mascia F., Mariani V., Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J. Invest. Dermatol. 2008, 128:1365-1374.
Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:2002-2007.
Rendu F., Eldor A., Grelac F., Bachelot C., Gazit A., Gilon C., Levy-Toledano S., Levitzki A. Inhibition of platelet activation by tyrosine kinase inhibitors. Biochem. Pharmacol. 1992, 44:881-888.
Saito K., Horiuchi K., Kimura T., Mizuno S., Yoda M., Morioka H., Akiyama H., Threadgill D., Okada Y., Toyama Y., Sato K. Conditional inactivation of TNFalpha-converting enzyme in chondrocytes results in an elongated growth plate and shorter long bones. PLoS One 2013, 8:e54853.
Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12:5268-5272.
Schneider M.R., Sibilia M., Erben R.G. The EGFR network in bone biology and pathology. Trends Endocrinol. Metab. 2009, 20:517-524.
Seshacharyulu P., Ponnusamy M.P., Haridas D., Jain M., Ganti A.K., Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:15-31.
Shilo B.Z. Signaling by the Drosophila epidermal growth factor receptor pathway during development. Exp. Cell Res. 2003, 284:140-149.
Shum L., Sakakura Y., Bringas P., Luo W., Snead M.L., Mayo M., Crohin C., Millar S., Werb Z., Buckley S., et al. EGF abrogation-induced fusilli-form dysmorphogenesis of Meckel's cartilage during embryonic mouse mandibular morphogenesis in vitro. Development 1993, 118:903-917.
Sibilia M., Wagner B., Hoebertz A., Elliott C., Marino S., Jochum W., Wagner E.F. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 2003, 130:4515-4525.
Sibilia M., Kroismayr R., Lichtenberger B.M., Natarajan A., Hecking M., Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007, 75:770-787.
Soltoff S.P. Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling. J. Biol. Chem. 2004, 279:10910-10918.
Steel R.G.D., Torrie J.H. Analysis of covariance. Principles and Procedures of Statistics: A Biometrical Approach 1996, 401-437. (New York). 3d edition. McGraw-Hill (Ed.).
Szende B., Keri G., Szegedi Z., Benedeczky I., Csikos A., Orfi L., Gazit A. Tyrphostin induces non-apoptotic programmed cell death in colon tumor cells. Cell Biol. Int. 1995, 19:903-911.
Takeda H., Inoue H., Kutsuna T., Matsushita N., Takahashi T., Watanabe S., Higashiyama S., Yamamoto H. Activation of epidermal growth factor receptor gene is involved in transforming growth factor-beta-mediated fibronectin expression in a chondrocyte progenitor cell line. Int. J. Mol. Med. 2010, 25:593-600.
Tran T.C., Sneed B., Haider J., Blavo D., White A., Aiyejorun T., Baranowski T.C., Rubinstein A.L., Doan T.N., Dingledine R., Sandberg E.M. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res. 2007, 67:11386-11392.
Tse A.C., Ge W. Spatial localization of EGF family ligands and receptors in the zebrafish ovarian follicle and their expression profiles during folliculogenesis. Gen. Comp. Endocrinol. 2009, 167:397-407.
Wan J., Ramachandran R., Goldman D. HB-EGF is necessary and sufficient for Muller glia dedifferentiation and retina regeneration. Dev. Cell 2012, 22:334-347.
Wang Y., Ge W. Cloning of epidermal growth factor (EGF) and EGF receptor from the zebrafish ovary: evidence for EGF as a potential paracrine factor from the oocyte to regulate activin/follistatin system in the follicle cells. Biol. Reprod. 2004, 71:749-760.
Wang K., Yamamoto H., Chin J.R., Werb Z., Vu T.H. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem. 2004, 279:53848-53856.
Westerfield M. THE ZEBRAFISH BOOK 2007, University of Oregon Press, Eugene. 5th edition.
Zeng F., Singh A.B., Harris R.C. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp. Cell Res. 2009, 315:602-610.
Zhang X., Siclari V.A., Lan S., Zhu J., Koyama E., Dupuis H.L., Enomoto-Iwamoto M., Beier F., Qin L. The critical role of the epidermal growth factor receptor in endochondral ossification. J. Bone Miner. Res. 2011, 26:2622-2633.
Zhu J., Shimizu E., Zhang X., Partridge N.C., Qin L. EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J. Cell. Biochem. 2011, 112:1749-1760.
